Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)
Authors:
Ľ. Podracká 1; K. Matoušovic 2
Authors place of work:
I. klinika detí a dorastu Lékárskej fakulty UPJŠ a DFN Košice, Slovenská republika, prednostka prof. MUDr. Ľudmila Podracká, CSc.
1; Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA
2
Published in the journal:
Vnitř Lék 2013; 59(2): 113-118
Category:
Review
Motto: Je doba svítání v mnoha otázkách aetiologie a pathogenesy nefritid – a tím i doba důležitého vyjasňování v indikacích therapeutických. (prof. Pelnář, Nemoc Brightova, Spolek lékařů českých, 1932)
Summary
We summarize recommendations for glomerulonephritis treatment, established by internationally recognized experts in the field and sponsored by KDIGO (Kidney Disease Improving Global Outcomes). Up till now, the KDIGO review has been the most prestigious analysis of therapeutic trials on immunosuppressive treatment of glomerulonephritides. The 167 recommendations addresses the following forms of glomerulopathies: steroid-sensitive nephrotic syndrome and steroid resistant nephrotic syndrome in children; minimal change disease and idiopathic focal segmental glomerulosclerosis in children and adults; idiopathic membranous nephropathy; idiopathic membranoproliferative glomerulonephritis; glomerulonephritis associated with infection; immunoglobulin A nephropathy and Henoch-Schönlein purpura nephritis; lupus nephritis; pauci-immune focal and segmental necrotizing glomerulonephritis; and anti--glomerular basement membrane antibody glomerulonephritis. We focuse our attention on progress in this topic in the last decade.
Key words:
glomerulonephritis – treatment – immunosuppression
Zdroje
1. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. J Pediatr 1979; 95: 239–243.
2. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987; 62: 1102–1106.
3. Bargman JM. Management of minimal lesion glomerulonephritis: Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S3–S16.
4. Podracká L, Böör A, Šasinka M. Cyclosporin A versus cyklofosfamid v liečbě nefrotického syndromu detí. Čas Lék Česk 2008; 147: 38–43.
5. Dzúrik R, Šašinka M, Mydlík M et al. Nefrológia. Bratislava: Herba 2004.
6. Burgess E. Management of focal segmental glomerulosclerosis. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S26–S32.
7. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85–89.
8. Muirhead N. Management of idiopathic membranous nephropathy. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S47–S55.
9. Imbasciati E, Cagnoli L, Case N et al. Controlled study of treatment of steroids and chlorambucil, in alternate months, for membranous nephropathy and focal glomerulosclerosis. Preliminary evaluation of the results. Minerva Nefrol 1980; 27: 571–575.
10. Levin A. Management of membranoproliferative glomerulonephritis. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S41–S46.
11. Nolin L, Courteau M. Management of IgA nephropathy. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S56–S62.
12. Bedogna V, Valvo E, Casagrande P et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990; 38: 101–107.
13. Donadio jr. JV, Grande JP, Bergstralh EJ et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10: 1772–1777.
14. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S33–S40.
15. Coggins CH. Is membranous nephropathy treatable? Am J Nephrol 1981; 1: 219–221.
16. Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 1990; 74: 133–156.
17. Bagga A, Sharma A, Srivastava RN. Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Pediatr Nephrol 1997; 11: 415–417.
18. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010; 11: CD003594.
19. Kurman MR. Recent clinical trials with levamisole. Ann N Y Acad Sci 1993, 685: 269–277.
20. Niaudet P, Drachman R, Gagnadoux MF et al. Treatment of idiopathic nephrotic syndrome with levamisole. Acta Paediatr Scand 1984; 73: 637–641.
21. Glassock RJ. Therapy of idiopathic nephrotic syndrome in adults. A conservative or aggressive therapeutic approach? Am J Nephrol 1993; 13: 422–428.
22. Schieppati A, Perna A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev 2004; 4: CD004293.
23. Janeček M, Říhová Z, Tesař V et al. Naše zkušenosti s léčbou membranózní nefropatie cyklosporinem. Vnitř Lék 2005; 51: 504–509.
24. Mestecky J, Raska M, Julian BA et al. IgA Nephropathy: Molecular Mechanisms of the Disease. Annu Rev Pathol. 2012, Oct 18. [Epub ahead of print].
25. Hogg RJ, Lee J, Nardelli N et al. Southwest Pediatric Nephrology Study Group. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 467–474.
26. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 2001; 12: 846–847.
27. Bohle A, Kressel G, Müller CA et al. The pathogenesis of chronic renal failure. Pathol Res Pract 1989; 185: 421–440.
28. Matoušovic K, Rossmann P. Primary glomerulonephritis. Morphological and clinical aspects of diagnosis and prognosis. Praha: Academia 1994.
29. Patel P, Pal S, Ashley C et al. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol Dial Transplant 2005; 20: 985–987.
30. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354:1961–1963.
31. Praga M, Hernández E, Montoyo C et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20: 240–248.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2013 Číslo 2
Najčítanejšie v tomto čísle
- Aortic regurgitation
- Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)
- Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma – experience with the use of recombinant human thyrotropin
- Heart transplantation and the subsequent treatment of AL amyloidosis